Trial Parameters
Condition Skin Cancer Melanoma
Sponsor Nuvana Healthcare LTD
Study Type OBSERVATIONAL
Phase N/A
Enrollment 100
Sex ALL
Min Age 18 Months
Max Age N/A
Start Date 2025-10-01
Completion 2025-12-01
Interventions
Smartphone-based AI skin lesion analysis (NuvanaDx platform).
Brief Summary
This study evaluates the feasibility and accuracy of an AI-powered mobile platform (NuvanaDx) for early detection of skin cancer, including melanoma, using smartphone-based imaging. The platform is designed to improve access to early diagnosis, reduce waiting times, and support triage into appropriate care pathways.
Eligibility Criteria
Inclusion Criteria: Adults (≥18 years) presenting with skin lesions suspicious for malignancy. Ability to provide informed consent. Exclusion Criteria: Inability to provide informed consent. Poor-quality images unsuitable for AI analysis.